

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q84193

Akihiro UMEZAWA, et al.

Appln. No.: National Stage Entry of PCT/JP03/04812

Confirmation No.: Not yet assigned Group Art Unit: Not yet assigned

Filed: October 18, 2004 Examiner: Not yet assigned

For: METHOD OF FORMING PANCREATIC B CELLS FROM MESENCHYMAL

CELLS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

10/511629

DT05 PCT/PT0 18 OCT 2084".



U.S. Appln. No.: National Stage Entry of PCT/JP03/04812

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 30,764

Gordon Kit

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373

CUSTOMER NUMBER

GK/lck

Date: October 18, 2004

10/511629

MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

U1050000 picke ly who will 18 OCT 2004						
Application Number	National Stage Entry of PCT/JP03/04812					
Confirmation Number	Not yet assigned ·					
Filing Date	October 18, 2004					
First Named Inventor	Akihiro UMEZAWA, et al.					
Art Unit	Not yet assigned					
Examiner Name	Not yet assigned					
Attorney Docket Number	Q84193					

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number				
		Numi	Kin Coc (if kno	le ² MM-DD-YYYY	Name of Patentee or Applicant of Lited Document	
		US				
		US				
		US	· · · · · · · · · · · · · · · · · · ·			
		US				
		US				
		US				
		US				
		US				
		US				

			F	OREIGN PA	TENT DOCUMI	ENTS	
Examiner Initials*	Cite No.¹	Foreign Patent Document		Publication Date	Name of Patentee or		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
						_	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1						
		SILVER, K. et al., ARIP cells as a model for pancreatic beta cell growth and development, Pancreas, 2001, Vol. 22, No. 2, pages 141 to 147					
		RAWDON, B.B. et al., Development of embryonic chick insulin cells in culture: Beneficial effects of serum-free, medium, reised nutrient, and biomatrix, In Vitro Cellular & Developmental Biology Animal, 1997, Vol. 33, No. 10, pages 774 to 782					
		HART, A.W. et al., Attenuation of FGF signaling in mouse beta-cells leads to diabetes, Nature, 2000, Vol. 408, No. 6814, pages 864 to 868					
		NIEUWENHUIZEN, A.G. et al., Progesterone stimulates pancreatic cell proliferation in viro, Eur. J. Endocrinol., 1999, Vol. 140, No. 3, pages 256 to 263					
		FERBER, S. et al., Pancreatic and duodenal homebox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia, Nat. Med., 2000, Vol. 6, No. 5, pages 568 to 572					
		CRISERA, C.A., et al., Expression and role of laminin-1 in mouse pancreatic organogenesis, Diabetes, 2000, Vol. 49, No. 6, pages 936 to 944					
		KERR-CONTE, et al. Ductal cyst formation in collagen-embedded adult human islet preparations. A means to the reproduction of nesidioblastosis in vitro, Diabetes, 1996, Vol. 45, No. 8, pages 1108 to 1114					
		LUMELSKY, N. et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets, Science, 2001, Vol. 292, No. 5520, pages 1389 to 1394					
		SORIA, B. et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice, Diabetes, 2000, Vol. 49, No. 2, pages 157 to 162					
		PITTENGER, M.F. et al., Multilineage potential of adult human mesenchymal stem cells, Science, 1999, Vol. 284, No. 5411, pages 143 to 147					
		RAMIYA, V.K. et al., Reversal of insulin-dependent diabetes using islets generated in vitro form pancreatic stem cells, Nat. Med., 2000, Vol. 6, No. 3, pages 278 to 282					
		MBALAVIELE, G. et al., Human mesenchymal stem cells promote human osteoclast differentiation from CD34=bone marrow hematopoietic progenitors, Endocrinology, 1999, Vol. 140, No. 8, pages 3736 to 3743					

	 		T	
Examiner Signature		Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.